CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 172.65 AUD 0.13% Market Closed
Market Cap: 83.8B AUD
Section:
 

Relative Value

The Relative Value of one CSL stock under the Base Case scenario is hidden AUD. Compared to the current market price of 172.65 AUD, CSL Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSL Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.6
P/S
P/S
Price to Sales
3.6
vs History
98
vs Industry
60
Median 3Y
6.3
Median 5Y
7.9
Industry
7.9
Forward
3.5
More Details
18.6
P/E
P/E
Price to Earnings
18.6
vs History
98
vs Industry
6
Median 3Y
36
Median 5Y
37.9
Industry
23.7
Forward
16.4
More Details
15.7
P/OCF
P/OCF
Price to OCF
15.7
vs History
98
vs Industry
7
Median 3Y
32.5
Median 5Y
32.3
Industry
22
More Details
40.2
P/FCFE
P/FCFE
Price to FCFE
40.2
vs History
61
vs Industry
4
Median 3Y
54
Median 5Y
54.6
Industry
24.3
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
98
vs Industry
23
Median 3Y
5.2
Median 5Y
5.9
Industry
3.3
More Details
4.1
EV/S
EV/S
Enterprise Value to Sales
4.1
vs History
98
vs Industry
47
Median 3Y
7
Median 5Y
7.7
Industry
8.2
Forward
4
More Details
8
EV/GP
EV/GP
Enterprise Value to Gross Profit
8
vs History
98
vs Industry
36
Median 3Y
13.5
Median 5Y
14.3
Industry
10.2
More Details
12.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.6
vs History
98
vs Industry
8
Median 3Y
21.9
Median 5Y
23.1
Industry
6.1
Forward
11.6
More Details
15.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.7
vs History
98
vs Industry
7
Median 3Y
27.2
Median 5Y
28.4
Industry
6.5
Forward
13.4
More Details
18.1
EV/OCF
EV/OCF
Enterprise Value to OCF
18.1
vs History
98
vs Industry
5
Median 3Y
35.8
Median 5Y
33.1
Industry
7.9
More Details
25.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
25.2
vs History
98
vs Industry
3
Median 3Y
71.2
Median 5Y
66.8
Industry
6.3
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
98
vs Industry
43
Median 3Y
3
Median 5Y
3.3
Industry
5.7
More Details

Multiples Across Competitors

CSL Competitors Multiples
CSL Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CSL Ltd
ASX:CSL
83.6B AUD 3.6 18.6 12.6 15.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 766 261.7 -160 486 -194 881.2 -192 657.4
US
Abbvie Inc
NYSE:ABBV
406.4B USD 6.8 172.7 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
177B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
153.1B USD 5.2 18.8 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.8 31.4 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.4 -532.4 -579.7 -564.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.5B USD 5.7 17.8 17 19.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD 16.4 1 206.2 162.6 197.3
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.3 33.6 57.9 59.5
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.6 -66.4 -60
P/S Multiple
Revenue Growth P/S to Growth
AU
CSL Ltd
ASX:CSL
Average P/S: 3 069 857.7
3.6
5%
0.7
FR
Pharnext SCA
OTC:PNEXF
33 766 261.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 086.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
AU
CSL Ltd
ASX:CSL
Average P/E: 190.5
18.6
11%
1.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 486 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
10%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 206.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.6
40%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 40.1
12.6
8%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 881.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.6
N/A N/A
NL
argenx SE
XBRU:ARGX
57.9
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 46.3
15.7
11%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 657.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.3
N/A N/A
NL
argenx SE
XBRU:ARGX
59.5
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60 N/A N/A

See Also

Summary
CSL intrinsic value, competitors valuation, and company profile.
DCF Valuation
CSL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CSL stock valuation using valuation multiples.
Wall Street Estimates
CSL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CSL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 306,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.